CrowdGather Partners with Human Pheromone Sciences to Launch "Made for Social Media" Patent Pending Attraction Fragrance
May 17 2011 - 7:00AM
Business Wire
One of the leading networks of forum communities on the
Internet, CrowdGather (OTCBB: CRWG) today announced that it has
acquired brand assets from Human Pheromone Sciences, Inc. (OTCBB:
EROX), a company engaged in the research, development,
manufacturing and marketing of consumer products containing
synthetic human pheromones. CrowdGather will partner with Human
Pheromone Sciences to launch and distribute Erox®, a unisex
fragrance, which has been proven to increase feelings of arousal,
excitement, social warmth and friendliness in both female and male
users. The fragrance will be launched, sold and marketed through
the use of social media and forum communities. Erox® will be the
first commercial product to contain Human Pheromone Sciences’
patent pending ER303 compound which has been shown to increase
feelings of attraction and flirtiness in both males and females
during a double blind placebo controlled study.
The new venture will provide CrowdGather with the opportunity to
expand its offerings as it seeks to utilize social media in unique
ways to efficiently take products to market.
“Forums provide a platform for people to discuss and recommend
products that matter most to them,” said CrowdGather CEO Sanjay
Sabnani. “Partnering with strategic partners to create exclusive
products for marketing through social media and forum communities
will provide us with greater control over our future revenue
streams and also showcase how powerful a channel this can be for
launching and selling future products.”
As part of the agreement CrowdGather will acquire the Erox.com
domain name and trademarks from Human Pheromone Sciences, and make
a strategic investment in the company via a private placement at
the time a final product is accepted by CrowdGather. Human
Pheromone Sciences will design and contract out the manufacture of
the fragrance for CrowdGather and its distribution partners.
"Our company has had a long standing relationship with
CrowdGather's CEO and we are delighted to have them as a partner in
bringing this product to market via the Internet. While we have had
a history of our compounds being used in successful fragrance
products, this is the first time we are launching a new product
using nontraditional channels. We are very excited at the
prospects,” commented William P. Horgan, CEO of Human Pheromone
Sciences.
Human pheromones are naturally occurring substances that trigger
specific behavioral or physiological response. Erox will be the
only commercial product to contain the combination of ER303 and
patented human pheromone compounds Androstadienone and
Estratetraenoll, both of which can be found in iconic brands such
as Avon’s Perceive® , Victoria’s Secret’s Very Sexy®, Henkel’s hair
care line, got2b®, and selected Dial Corporation body washes. Erox®
will be the first commercial product to contain ER303 which bears a
structural similarity to human pheromones, but is instead derived
from a species of sea coral.
About CrowdGather, Inc.
With its growing portfolio of special interest forums and
enthusiast message board communities, CrowdGather
(www.crowdgather.com) has created a centralized network to benefit
forum members, forum owners and forum advertisers. CrowdGather
provides a highly interactive and informational social network for
members, a management and revenue-sharing resource for third-party
forum owners, and a largely untapped advertising network for
marketers worldwide.
About Human Pheromone Sciences, Inc.
Human Pheromone Sciences, Inc. is a technology-based company,
whose proof-of concept products included prestige-priced fragrances
and toiletries and environmental products sold under the Natural
Attraction®, REALM®, innerREALM® and EROX® trademarks. These
products contain mood-enhancing compounds, whose efficacy has been
validated at leading universities around the world, and whose use
is covered under United States and foreign patents. The Company is
also involved in research and product development efforts on new
compounds that have been previously identified as stimulating the
emotional centers of the human brain.
This press release contains forward-looking statements (as
defined in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended)
concerning future events and the Company’s growth and business
strategy. Words such as “expects,” “will,” “intends,” “plans,”
“believes,” “anticipates,” “hopes,” “estimates,” and variations on
such words and similar expressions are intended to identify
forward-looking statements. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, no assurance can be given that such expectations will
prove to have been correct. These statements involve known and
unknown risks and are based upon a number of assumptions and
estimates that are inherently subject to significant uncertainties
and contingencies, many of which are beyond the control of the
Company. Actual results may differ materially from those expressed
or implied by such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not
limited to, changes in the Company’s business; competitive factors
in the market(s) in which the Company operates; risks associated
with operations outside the United States; and other factors listed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in the Company’s expectations with respect
thereto or any change in events, conditions or circumstances on
which any statement is based.
Human Pheromone Sciences (GM) (USOTC:EROX)
Historical Stock Chart
From May 2024 to Jun 2024
Human Pheromone Sciences (GM) (USOTC:EROX)
Historical Stock Chart
From Jun 2023 to Jun 2024